Shay Wahl would be the first to tell you that patience isn’t her strong suit. But she’s working on it through her hobbies.

A panelist discusses how National Comprehensive Cancer Network (NCCN) guidelines have influenced molecular testing in ovarian cancer, highlighting the importance of biomarkers like BRCA genes for ...

Whether it’s gardening or foraging for wild mushrooms near their property in Freeburg, Missouri, Shay Wahl and her husband James bond by spending time outside.A ...

Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at ...

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

The phase III ROSELLA study evaluated its pipeline candidate, relacorilant, in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer. The ROSELLA study met ...

The company has reported promising results from its Phase 3 ROSELLA trial ... nab-paclitaxel for patients with platinum-resistant ovarian cancer. Median progression-free survival improved to ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

The phase III ROSELLA study evaluated relacorilant in combination with nab-paclitaxel for treating patients with recurrent, platinum-resistant ovarian cancer. Data from the same showed that ...